As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, Wegovy, and Mounjaro. The research involved over two million patients and found that those using these medications have double the risk of developing pancreatitis – a potentially life-threatening inflammation of the pancreas.

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, potentially paving the way for broader treatments.

( MENAFN - Swissinfo) Swiss medicines regulator Swissmedic has taken legal action against media houses in Switzerland for what they argue is unauthorised advertising for drugs used for weight loss like Ozempic and Wegovy. Swiss media say this amounts to censorship.

Weight-loss jabs could reduce your risk of drug abuse, seizures and pneumonia, as well as heart attacks and strokes, scientists have found. Last year, research revealed that weight-loss jabs – or GLP-1RAs – such as Wegovy and Ozempic could reduce the risk of heart attack and stroke.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.